Eris Lifesciences Q4 FY26 Results: PAT Rs 280 Cr

Eris Lifesciences Q4 FY26 results were declared on May 20, 2026. Eris Lifesciences reported PAT of Rs 280 crore for the quarter ended March 31, 2026, up 174% YoY compared to Rs 102 crore in Q4 FY25. Revenue from operations stood at Rs 757 crore, up 7% YoY. Gross profit was Rs 204 crore (up 16% YoY). The results are on a Consolidated basis. Eris Lifesciences is a Branded Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Eris Lifesciences Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	757	705	+7%
Gross Profit	204	175	+16%
Net Profit	280	102	+174%
Basis	Consolidated

Note: Exceptional quarter: PAT surged 174% YoY to Rs 280 crore on revenue of Rs 757 crore (+7% YoY). Gross profit +16% to Rs 204 crore. Eris Lifesciences Q4 FY26 results declared May 20, 2026. Verify from BSE/NSE audited filings.

Eris Lifesciences Q4 FY26 Performance Analysis

The Eris Lifesciences Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. The quarter demonstrates a meaningful improvement in profitability. Eris Lifesciences operates in the Branded Pharmaceuticals space, a sector shaped by domestic consumption trends, input costs, and India’s macro environment in FY26.

The 174% YoY PAT growth in Eris Lifesciences Q4 FY26 reflects operational improvements, better cost management, and revenue scale benefits.

Screen the best stocks on the Univest Screener.

Key Factors Driving Eris Lifesciences Q4 FY26 Results

Revenue Performance in Q4 FY26

Eris Lifesciences Q4 FY26 revenue of Rs 757 crore was up 7% YoY. Revenue was broadly stable, reflecting a steady operating environment for the Branded Pharmaceuticals business.

Profitability and Margin Trends

The Eris Lifesciences Q4 FY26 PAT of Rs 280 crore (up 174% YoY) reflects strong operating leverage and margin expansion in the Branded Pharmaceuticals business.

India Macro Tailwinds in Q4 FY26

The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, strong government capital expenditure, and resilient urban and rural consumption. The RBI’s accommodative policy stance supported demand conditions across consumer and industrial sectors. For Eris Lifesciences, operating in the Branded Pharmaceuticals space, this macro environment provided a constructive demand backdrop during the quarter.

FY27 Outlook for Eris Lifesciences

Following Eris Lifesciences Q4 FY26 results, investors will track management commentary on FY27 revenue guidance, margin trajectory, capex plans, and competitive positioning. The Branded Pharmaceuticals sector continues to benefit from India’s structural growth story, rising middle-class consumption, and infrastructure investment cycle.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on Eris Lifesciences Q4 FY26

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.